2009年7月
VEGF in Patients with Non-small Cell Lung Cancer during Combination Chemotherapy of Carboplatin and Paclitaxel
ANTICANCER RESEARCH
- ,
- ,
- ,
- ,
- ,
- ,
- ,
- 巻
- 29
- 号
- 7
- 開始ページ
- 2635
- 終了ページ
- 2639
- 記述言語
- 英語
- 掲載種別
- 研究論文(学術雑誌)
- 出版者・発行元
- INT INST ANTICANCER RESEARCH
Background: Vascular endothelial growth factor (VEGF) is a potent angiogenic factor related to tumor growth and metastasis. However, little is known about the clinical significance of circulating VEGF in cancer patients. Patients and Methods: Eighteen patients with non-small cell lung cancer received chemotherapy using carboplatin and paclitaxel. Plasma levels of VEGF were analyzed at baseline and after 2 cycles of chemotherapy. Results: Partial remission was observed in 3 patients (16.7%), stable disease in 10 patients (55.6%) and progressive disease in 5 patients (27.8%). Patients with partial remission or stable disease had significantly lower levels of plasma VEGF than did patients with progressive disease, both at baseline (p=0.0341) and after 2 cycles of chemotherapy (p=0.0265). There were no significant changes of plasma VEGF during chemotherapy. Conclusion: Pretreatment plasma levels of VEGF are a useful marker for predicting disease control by chemotherapy.
- リンク情報
- ID情報
-
- ISSN : 0250-7005
- PubMed ID : 19596939
- Web of Science ID : WOS:000268104100031